# Eckuity

> Eckuity is a VC fund backing Health Care and Manufacturing. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 9
- Last investment: Jun 2026
- Lead investor: 56%
- Last updated: Aug 2026
- Website: https://eckuity.com/

Eckuity is a Strategic venture capital investment that translates great science into tomorrow’s healthcare.

## Contacts

5 contacts available for Eckuity. Shizune tracks 1 team members at Eckuity. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/eckuity?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 44% |
| Manufacturing | 3 | 33% |
| Medical Device | 3 | 33% |
| Medical | 2 | 22% |
| Biotechnology | 2 | 22% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 3 | 33% |
| Series C | 2 | 22% |
| Venture - Series Unknown | 2 | 22% |
| Seed | 1 | 11% |
| Private Equity | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 44% |
| United Kingdom | 3 | 33% |
| Canada | 1 | 11% |
| Israel | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Mark Goldstone | Partner | 1 | https://shizune.co/investors/profile/mark-goldstone |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Automata | Automata is a deep-tech company that creates products that empower people to automate physical work. The company's product, Eva, is a lightweight and affordable robot arm built for professionals in a production line, in a lab, a home workshop or even in a classroom. People don't need to be technical experts to communicate with robots. Theweb-based software platform can be programmed by anyone, anywhere, any time, from any device, making it easy to reconfigure for a wide range of different tasks.Automata was founded on 2015 and is headquartered in London, England. |  | Series C | Jun 25, 2026 |  |
| Kardium | Kardium is a medical solutions company that develops a globe pulsed field system for the diagnosis and treatment of atrial fibrillation. Its flagship Globe Pulsed Field System integrates high-definition mapping, pulmonary vein isolation, and atrial ablation into a single spherical catheter featuring 122 electrodes. | $250.2M | Private Equity | Jul 02, 2025 |  |
| Ansella Therapeutics | Ansella Therapeutics is a specialized pharmaceutical firm focused on developing new treatment for women's health using materials science. |  | Seed | Mar 15, 2024 |  |
| Avive Solutions | Avive Solutions develops a next-generation Automated External Defibrillator (AED) and software solutions. Avive's AED enables anyone to positively impact the outcome of a Sudden Cardiac Arrest (SCA) rescue by building a more robust solution that addresses the problem of SCA in its entirety. The AED will remove barriers to respond to a SCAscenario. It will be easy to purchase, easy to access in an emergency, easy to keep maintained, and most importantly easy to use effectively when it matters most.Avive Solutions is headquartered in San Francisco, California. | $56.5M | Series B | Feb 14, 2024 |  |
| AWAK Technologies | AWAK Technologies develop wearable dialysis machines, 1kg and battery-operated, for continuous dialysis. The company was certified by SGS for ISO 13485 Quality Management System in September 2008 with the scope of designing, manufacturing and distributing medical devices.The Automated Wearable Artificial Kidney (AWAK) is based on tidalperitoneal dialysis. The technology is based on research by Profs David Lee & Martin Roberts of UCLA and VA Systems.The engineering and development of AWAK is done in Singapore with the collaboration of Temasek Polytechnic.The company has completed the R&D and is now in the clinical trial stage, targeting both FDA and CE certifications. The AWAK Regular Cartridge, is currently in pilot production stage and expected to enter clinical trial by the end of 2012. This wearable artificial kidney operates continuouslyand functions like a normal kidney. Being small , light (less than 1 kg) and battery-operated, the patients will be able to go about having daily routines, with no restriction to lifestyles such as work, travel and leisure. | $20M | Series B | Sep 13, 2023 |  |
| Sanoculis | Sanoculis is a medical device start-up company that develops an innovative surgical procedure for the treatment of the Glaucoma. The company offers a new alternative surgical procedure for treating glaucoma. Its Minimally Invasive Micro Sclerostomy (MIMS) solution consists of a single-patient-use sterile tool and a multi-use external machine. Inthe course of the surgery, a sclero-corneal drainage channel is created to reduce intraocular pressure.MIMS is a microfluidic full-thickness procedure developed as an advanced laser sclerotomy. The technique uses a cutting and drilling device to reduce trauma to the surrounding tissue, minimizing scar tissue formation and allowing for a long-lasting filtering bleb. The MIMS channel ensures a controlled fluid flow with minor complications.The company was founded in 2012 and is based in Tel Aviv, Israel |  | Series C | Jan 25, 2023 |  |
| Professional Triathletes Organisation | Professional Triathletes Organisation is a nonprofit company that organizes events of the triathlon sport. | $30M | Series B | Dec 23, 2022 |  |
| Sonrai Analytics | Sonrai develop applications and interfaces to utilize the data and the resultant outputs of analysis and combine this with AI and ML to make your data predictive. |  | Venture - Series Unknown | Nov 10, 2022 |  |
| Mobius Biomedical | Mobius Biomedical plans to bring unprecedented efficiencies to the development and manufacturing of biologics and biosimilars, and reduce their cost by over 90% at commercial scale. The Company has developed new design, new process and new equipment to drastically reduce the capex, opex and facility footprint of manufacturing plants whilemaintaining the purity, throughput and efficiency at commercial scale. |  | Venture - Series Unknown | Mar 28, 2022 |  |

9 of 9 investments shown.

## Co-investors
- [Advanced MedTech](https://shizune.co/investors/profile/accuron-medtech) — VC Fund, 1 deal together
- [Catalyst Health Ventures](https://shizune.co/investors/profile/catalyst-health-ventures) — VC Fund, 1 deal together
- [Danaher](https://shizune.co/investors/profile/danaher) — VC Fund, 1 deal together
- [Warner Bros Discovery](https://shizune.co/investors/profile/discovery-inc) — VC Fund, 1 deal together
- [Divergent Investments](https://shizune.co/investors/profile/divergent-investments) — VC Fund, 1 deal together
- [DNV capital](https://shizune.co/investors/profile/dnv-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Eckuity invest in?

Eckuity invests primarily in Health Care, Manufacturing and Medical Device startups, most often at Series B and Series C stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Eckuity?

Public channels for Eckuity include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Eckuity?

The team at Eckuity includes Mark Goldstone (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co